SEC filings
Amgen (AMGN)
Recent filings Amgen made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000318154All filings on SEC.gov
10-QQuarterly report
Quarterly report
Amgen reported third-quarter 2026 total revenues of $10.365 billion, up 8%, and net income of $3.864 billion, or $7.08 diluted EPS, while disclosing positive Phase 3 results for TEZSPIRE in eosinophilic esophagitis, IMDELLTRA/IMDYLLTRA in…
8-KCurrent report
Results of Operations and Financial Condition
Amgen reported third-quarter 2026 total revenues rose 8% to $10.4 billion and GAAP EPS rose 19% to $7.08, while non-GAAP EPS increased 14% to $6.45. CEO Robert A. …
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Amgen appointed David W. Gibbs, former CEO of Yum! Brands, to its board of directors effective October 26, 2026; he will serve on the Audit Committee and the Compensation and Management Development Committee. …
10-QQuarterly report
Quarterly report
Amgen reported second-quarter 2026 total revenues of $10.05 billion, net income of $2.38 billion, and diluted EPS of $4.37, with product sales up 9% to $9.54 billion, and said the European Commission granted marketing authorization for…
8-KCurrent report
Results of Operations and Financial Condition
Amgen reported second-quarter 2026 total revenues of $10.1 billion, up 10% year over year, with GAAP earnings per share of $4.37 versus $2.65 a year earlier and non-GAAP earnings per share of $6.29 versus $6.02. …
8-KCurrent report
Material Cybersecurity Incidents
Amgen determined that a July 2026 cybersecurity incident involving unauthorized activity in third-party cloud environments is material, after proprietary data and patient protected health information were exfiltrated. …
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Amgen in Readster
Add Amgen to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.